Keith Pietropaolo - Atea PharmaceuticalsI Senior Sciences
| AVIR Stock | USD 3.67 0.06 1.66% |
Executive
Keith Pietropaolo is Senior Sciences of Atea PharmaceuticalsInc
| Address | 225 Franklin Street, Boston, MA, United States, 02110 |
| Phone | 857 284 8891 |
| Web | https://ateapharma.com |
Atea PharmaceuticalsI Management Efficiency
The company has return on total asset (ROA) of (0.1556) % which means that it has lost $0.1556 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2916) %, meaning that it created substantial loss on money invested by shareholders. Atea PharmaceuticalsI's management efficiency ratios could be used to measure how well Atea PharmaceuticalsI manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/02/2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.31. At this time, Atea PharmaceuticalsI's Non Current Assets Total are relatively stable compared to the past year. As of 06/02/2024, Non Currrent Assets Other is likely to grow to about 1.5 M, while Net Tangible Assets are likely to drop slightly above 398.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Boyer | Neurocrine Biosciences | 44 | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| William Hartzel | Emergent Biosolutions | N/A | |
| Ingrid Delaet | Neurocrine Biosciences | 57 | |
| Dimitri Grigoriadis | Neurocrine Biosciences | 66 | |
| Sonya Ghobrial | Haleon plc | 50 | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
| Darin Esq | Neurocrine Biosciences | 58 | |
| Haywood Miller | Emergent Biosolutions | N/A | |
| Bjorn Timelin | Haleon plc | N/A | |
| Robert Burrows | Emergent Biosolutions | N/A | |
| Ed Petter | Haleon plc | N/A | |
| John Pearson | PetIQ Inc | N/A | |
| Bjarne Tellmann | Haleon plc | 57 | |
| Kyle Gano | Neurocrine Biosciences | 51 | |
| Namrata Patel | Haleon plc | 58 | |
| Kelly Warfield | Emergent Biosolutions | N/A | |
| William Carter | PetIQ Inc | N/A | |
| Matthew Abernethy | Neurocrine Biosciences | 44 | |
| Franck Riot | Haleon plc | 56 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.16 |
Atea PharmaceuticalsInc Leadership Team
Elected by the shareholders, the Atea PharmaceuticalsI's board of directors comprises two types of representatives: Atea PharmaceuticalsI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atea. The board's role is to monitor Atea PharmaceuticalsI's management team and ensure that shareholders' interests are well served. Atea PharmaceuticalsI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atea PharmaceuticalsI's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Exec Officer | ||
| XiaoJian Zhou, Executive Development | ||
| Jayanthi Wolf, Executive Affairs | ||
| Wayne CPA, Executive Officer | ||
| Ariyapadi Krishnaraj, Vice Marketing | ||
| JeanPierre Sommadossi, Chairman, Founder | ||
| John Vavricka, Chief Officer | ||
| Nancy Agrawal, Executive Development | ||
| Maria MD, Chief Officer | ||
| Jonae Barnes, Senior Communications | ||
| Andrea JD, Executive CFO | ||
| Keith Pietropaolo, Senior Sciences | ||
| Adel Moussa, Executive Chemistry |
Atea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atea PharmaceuticalsI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.16 | ||||
| Current Valuation | (230.18 M) | ||||
| Shares Outstanding | 84.22 M | ||||
| Shares Owned By Insiders | 9.56 % | ||||
| Shares Owned By Institutions | 66.68 % | ||||
| Number Of Shares Shorted | 1.87 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 0.57 X | ||||
| Price To Sales | 1.90 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Atea Stock analysis
When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.641 | Earnings Share (1.95) | Revenue Per Share 2.31 | Quarterly Revenue Growth 2.952 | Return On Assets (0.16) |
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Atea PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.